Global X Genomics & Biotechnology ETF
Price through Oct 1 · Flows through Aug 23. Figures use the latest available records, not a live quote. Fund details retrieved Oct 1. Holdings snapshot retrieved Oct 1.
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
SOURCE: MARKET TAPE & DAILY CREATION/REDEMPTION RECORDS · 3Y SHOWN · NET −$93M OVER THIS RANGE
Recent fund-flow records are unavailable, while the price has returned +51.3% so far this year. At 0.50% a year it is not the cheapest way in — FDHT has a reported fee of 0.39%.
COMPOSED FROM THE FUND’S OWN DAILY RECORDS · UPDATED WITH EACH REFRESH
CELL SIZE IS PORTFOLIO WEIGHT · COLOR IS THE CHANGE IN THE LATEST AVAILABLE SNAPSHOT · TOP 40 POSITIONS
| # | Holding | Weight | Price | Day | 52-wk | |
|---|---|---|---|---|---|---|
| 1 | MRNAMODERNA | 9.45% | $188.94 | -1.9% | ||
| 2 | TWSTTWIST BIOSCIENCE | 8.10% | $188.05 | -2.7% | ||
| 3 | TXG10X GENOMICS | 7.29% | $88.76 | -1.8% | ||
| 4 | ILMNILLUMINA | 5.72% | $265.72 | -2.9% | ||
| 5 | NTRANATERA | 5.43% | $408.47 | -1.2% | ||
| 6 | GHGUARDANT HEALTH | 5.44% | $174.75 | -2.0% | ||
| 7 | TECHBIO-TECHNE | 3.38% | $72.40 | -0.1% | ||
| 8 | VRTXVERTEX PHARMACEUTICALS | 3.26% | $506.74 | -3.1% | ||
| 9 | BMRNBIOMARIN PHARMACEUTICAL | 3.02% | $58.44 | -2.6% | ||
| 10 | QGENQIAGEN NV | 2.99% | $42.04 | -3.9% | ||
| 11 | CRSPCRISPR THERAPEUTICS AG | 2.68% | $55.44 | +0.2% | ||
| 12 | VCYTVERACYTE | 2.56% | $44.19 | -4.0% | ||
| 13 | BNTXBIONTECH SE | 2.47% | $96.85 | -1.5% | ||
| 14 | CAICaris Life Sciences | 2.63% | $28.35 | -7.4% | ||
| 15 | ARWRARROWHEAD PHARMACEUTICALS | 2.42% | $64.79 | -1.0% |
The full book, free with one sign-in.
Top 15 positions are open to everyone. Sign in once and every fund’s complete holdings — plus CSV export, watchlists, and flow alerts — unlock across the network.
Sign in to see all 41| 1 week | -2.0% |
| 1 month | +6.2% |
| 3 months | +19.0% |
| 6 months | +66.2% |
| YTD | +51.3% |
| 1 year | +72.5% |
| 3 years | — |
PRICE RETURN, DISTRIBUTIONS NOT REINVESTED
| 1 week | — |
| 1 month | — |
| 3 months | — |
| YTD | — |
| 1 year | — |
CREATION/REDEMPTION DOLLARS, DAILY RECORDS
The top holding is 9.4% of the book; the top ten carry 56%. Spread across 50+ names, it behaves like roughly 23 equally-weighted positions.
VOLATILITY & DRAWDOWN FROM THE DAILY TAPE · CONCENTRATION FROM THE LATEST DISCLOSED BOOK
| Most-traded holdings, options premium | Bullish | Bearish |
|---|---|---|
| MRNA MODERNA | $35M | $34M |
| LLY ELI LILLY | $30M | $32M |
| NTRA NATERA | $3M | $6M |
| BMY BRISTOL MYERS SQUIBB | $2M | $3M |
| QGEN QIAGEN NV | $2M | $2M |
TODAY’S OPTIONS PREMIUM IN THE FUND’S UNDERLYING NAMES
Due diligence cuts both ways. These funds sit on the same shelf and beat GNOM on at least one dimension that matters — the fee, the asset base, or where the money is going.
| Fund | Fee | Assets | Flow, 1M | The case | |
|---|---|---|---|---|---|
| SPDW State Street SPDR Portfolio Developed World ex-US ETF | 0.03% | $41.5B | +$286M | -47bp on fee · 490× the assets · +$286M in over the month | Head-to-head |
| BBUS JPMorgan BetaBuilders U.S. Equity ETF | 0.02% | $9.4B | +$187M | -48bp on fee · 111× the assets · +$187M in over the month | Head-to-head |
| SPMD State Street SPDR Portfolio S&P 400 Mid Cap ETF | 0.03% | $18.2B | +$199M | -47bp on fee · 215× the assets · +$199M in over the month | Head-to-head |
| SPYG State Street SPDR Portfolio S&P 500 Growth ETF | 0.04% | $56.2B | +$717M | -46bp on fee · 663× the assets · +$717M in over the month | Head-to-head |
| SPTM State Street SPDR Portfolio S&P 1500 Composite Stock Market ETF | 0.03% | $14.1B | +$235M | -47bp on fee · 167× the assets · +$235M in over the month | Head-to-head |